Donor Lymphocyte Infusion in Hematologic Malignancies – Good to be Fresh?

Conclusion We conclude that the use of fresh versus cryopreserved cells does not have an impact on outcomes and selected patients can achieve long term survival with DLI for treatment of post-transplant relapse though the overall outcomes remain dismal. Teaser Since its initial application in CML, donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis of 63 patients, we find that there is no difference in outcomes based on the type of cells utilized for a DLI. However, in a subset of 32 AML/MDS patients, use of cryopreserved cells appears to result in improved even free survival in patients who underwent a myeloablative transplant.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research